| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.91▼ | 1.92▼ | 1.91▼ | 1.92▼ | 1.94▼ |
| MA10 | 1.90▼ | 1.91▼ | 1.91▼ | 1.93▼ | 2.10▼ |
| MA20 | 1.90▲ | 1.91▼ | 1.92▼ | 1.97▼ | 2.21▼ |
| MA50 | 1.94▼ | 1.96▼ | 1.98▼ | 2.15▼ | 2.93▼ |
| MA100 | 2.00▼ | 2.12▼ | 2.17▼ | 2.19▼ | 3.20▼ |
| MA200 | 2.17▼ | 2.28▼ | 2.17▼ | 2.66▼ | 2.99▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.007▲ | 0.007▲ | 0.007▲ | 0.007▲ | 0.007▲ |
| RSI | 48.468▼ | 46.644▼ | 45.770▼ | 42.831▼ | 39.423▼ |
| STOCH | 68.210 | 68.210 | 68.210 | 34.140 | 10.531▼ |
| WILL %R | -50.000 | -50.000 | -50.000 | -60.870 | -88.312▼ |
| CCI | -1.360 | -4.911 | -23.158 | -54.824 | -106.849▼ |
|
Monday, May 19, 2025 11:05 AM
Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a ...
|
|
Wednesday, May 14, 2025 01:15 PM
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...
|
|
Monday, March 03, 2025 12:19 AM
Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 13/06/25 | 1.95 | 1.95 | 1.89 | 1.92 | 13,600 |
| 12/06/25 | 1.91 | 1.96 | 1.87 | 1.955 | 6,218 |
| 11/06/25 | 1.8801 | 1.9347 | 1.855 | 1.86 | 15,753 |
| 10/06/25 | 1.915 | 1.915 | 1.915 | 1.915 | 5,534 |
| 09/06/25 | 1.85 | 1.96 | 1.85 | 1.96 | 22,700 |
| 06/06/25 | 1.89 | 1.96 | 1.83 | 1.83 | 40,100 |
| 05/06/25 | 1.96 | 1.99 | 1.92 | 1.96 | 14,500 |
| 04/06/25 | 1.99 | 2.04 | 1.94 | 1.95 | 11,300 |
| 03/06/25 | 2.05 | 2.05 | 1.98 | 1.99 | 21,000 |
| 02/06/25 | 1.96 | 2.0074 | 1.9369 | 1.99 | 27,356 |
|
|
||||
|
|
||||
|
|